Supriya Lifescience H1 EBITDA margin drops 1,261 basis points

Supriya Lifescience Limited reported H1 FY27 revenue of Rs 396.04 crore, up 14.8% year on year, but its earnings before interest, tax, depreciation and amortisation (EBITDA) margin fell 1,261 basis points to 23.4% from 36.1%. EBITDA declined 25.3% to Rs 92.86 crore as cost of goods sold and other expenses increased faster than revenue.

How did Supriya Lifescience’s H1 FY27 profit change?

Supriya Lifescience’s H1 FY27 revenue growth did not carry through to operating profit or net profit. Revenue increased by Rs 51.13 crore from Rs 344.91 crore in H1 FY26, while EBITDA declined by Rs 31.49 crore to Rs 92.86 crore. Profit before tax fell 32.1% to Rs 78.57 crore, and profit after tax (PAT) declined 37.5% to Rs 53.29 crore from Rs 85.22 crore.

The margin movement shows the difference between the sales and profit trends. EBITDA margin was 23.4% in H1 FY27, compared with 36.1% a year earlier, while PAT margin declined to 13.5% from 24.7%. Thus, EBITDA fell despite the 14.8% rise in revenue, and PAT fell at a faster 37.5% rate than EBITDA.

Why did Supriya Lifescience’s EBITDA margin fall?

Supriya Lifescience’s disclosed cost lines rose faster than its 14.8% H1 FY27 revenue increase. Cost of goods sold increased 45.6% to Rs 127.45 crore from Rs 87.50 crore, and other expenses rose 41.0% to Rs 121.11 crore from Rs 85.89 crore. Employee benefits expense grew 15.8% to Rs 54.63 crore, broadly in line with the sales increase but below the growth in the two larger cost categories.

These movements reduced the amount left after operating costs. The combined increase in cost of goods sold and other expenses was Rs 75.17 crore, exceeding the Rs 51.13 crore increase in revenue. EBITDA consequently fell to Rs 92.86 crore, producing the 1,261-basis-point decline in margin; one basis point is one-hundredth of a percentage point. The presentation reports the cost changes but does not identify specific reasons for the increases.

Below EBITDA, depreciation and amortisation expense increased 40.6% to Rs 18.40 crore from Rs 13.09 crore in H1 FY26. Other income declined 8.5% to Rs 4.94 crore, while finance costs declined 10.3% to Rs 83 lakh. Total tax expense fell 17.2% to Rs 25.28 crore, but that reduction was smaller than the 32.1% decline in profit before tax, contributing to the 37.5% decrease in PAT.

Which Supriya Lifescience revenue mixes changed in H1 FY27?

Supriya Lifescience’s regional revenue mix shifted toward Asia and Europe in H1 FY27. Europe represented 40% of revenue, up from 39% in H1 FY26, while Asia increased to 38% from 33%. Latin America’s share declined to 16% from 19%, North America remained at 4%, and the Others category fell to 2% from 5%.

The therapy mix also changed within the listed therapeutic areas. Anesthetic remained the largest disclosed therapy area but declined to 48% of revenue from 54%, a six-percentage-point reduction. Vitamins increased to 16% from 12%, analgesic products rose to 6% from 2%, anti-histamine declined to 9% from 12%, and anti-asthmatic increased to 8% from 7%.

The presentation does not connect these regional and therapy changes directly to the decline in EBITDA margin. It does show, however, that revenue composition was different from H1 FY26 while H1 revenue rose to Rs 396.04 crore and EBITDA margin fell to 23.4%. The listed therapy-area percentages are revenue contributions for the top therapeutic areas disclosed by Supriya Lifescience.

How did Supriya Lifescience’s Q2 FY27 compare with Q2 FY26 and Q1 FY27?

Supriya Lifescience’s Q2 FY27 showed modest year-on-year revenue growth alongside a larger decline in operating profit. Revenue rose 3.2% to Rs 206.30 crore from Rs 199.83 crore in Q2 FY26, but EBITDA fell 37.5% to Rs 45.40 crore from Rs 72.65 crore. Q2 EBITDA margin was 22.0%, compared with 36.4% a year earlier, a decline of 1,435 basis points.

On a sequential basis, Q2 revenue was 8.7% higher than Q1 FY27 revenue of Rs 189.75 crore. EBITDA was 4.3% lower than Q1’s Rs 47.46 crore, and the EBITDA margin moved down 300 basis points from 25.0% in Q1 to 22.0% in Q2. Cost of goods sold rose 26.0% sequentially to Rs 71.06 crore, while other expenses increased 10.9% to Rs 63.69 crore.

Q2 PAT was Rs 29.25 crore, down 42.0% from Rs 50.43 crore in Q2 FY26 but up 21.7% from Rs 24.04 crore in Q1 FY27. The sequential PAT increase occurred as total tax expense declined to Rs 8.53 crore in Q2 from Rs 16.75 crore in Q1, even though Q2 profit before tax fell 7.4% sequentially to Rs 37.78 crore. Q2 earnings per share were Rs 5.04, compared with Rs 6.30 a year earlier and Rs 2.99 in Q1.

Conclusion

Supriya Lifescience delivered higher H1 FY27 revenue, with sales rising 14.8% to Rs 396.04 crore, but operating-cost growth was faster: cost of goods sold rose 45.6% and other expenses increased 41.0%. The resulting 1,261-basis-point EBITDA-margin decline to 23.4% coincided with a 25.3% fall in EBITDA and a 37.5% reduction in PAT.

The next result will show whether the Q2 EBITDA margin of 22.0%, below Q1’s 25.0%, persists or changes. Supriya Lifescience’s presentation does not disclose a margin-restoration target, a cost-control plan or a scheduled operating milestone, leaving the relationship between future revenue growth, cost of goods sold and other expenses unresolved.